Partial response to dabrafenib and trametinib in relapsed BRAF V600E-Mutated multiple myeloma and possible mechanisms of resistance

T Ernst, S Aebi, A Zander, T Zander - BMJ Case Reports CP, 2022 - casereports.bmj.com
BRAF V600E mutations are detected in 3%–10% of patients with multiple myeloma (MM)
and are associated with more aggressive disease, higher frequency of extramedullary …
被引用次数：6 相关文章

Partial response to dabrafenib and trametinib in relapsed BRAF V600E-Mutated multiple myeloma and possible mechanisms of resistance.

T Ernst, S Aebi, A Zander, T Zander - BMJ Case Reports, 2022 - europepmc.org
Abstract BRAF V600E mutations are detected in 3%–10% of patients with multiple myeloma
(MM) and are associated with more aggressive disease, higher frequency of extramedullary …
[HTML] nih.gov

[HTML][HTML] Partial response to dabrafenib and trametinib in relapsed BRAF V600E-Mutated multiple myeloma and possible mechanisms of resistance

T Ernst, S Aebi, A Zander, T Zander - BMJ Case Reports, 2022 - ncbi.nlm.nih.gov
Abstract BRAF V600E mutations are detected in 3%–10% of patients with multiple myeloma
(MM) and are associated with more aggressive disease, higher frequency of extramedullary …

Partial response to dabrafenib and trametinib in relapsed BRAF V600E-Mutated multiple myeloma and possible mechanisms of resistance

T Ernst, S Aebi, A Zander, T Zander - BMJ case reports, 2022 - pubmed.ncbi.nlm.nih.gov
BRAF V600E mutations are detected in 3%-10% of patients with multiple myeloma (MM) and
are associated with more aggressive disease, higher frequency of extramedullary growth …

Partial response to dabrafenib and trametinib in relapsed BRAF V600E-Mutated multiple myeloma and possible mechanisms of resistance

T Ernst, S Aebi, A Zander, T Zander - BMJ Case Reports, 2022 - search.proquest.com
Abstract BRAF V600E mutations are detected in 3%–10% of patients with multiple myeloma
(MM) and are associated with more aggressive disease, higher frequency of extramedullary …

Partial response to dabrafenib and trametinib in relapsed BRAF V600E-Mutated multiple myeloma and possible mechanisms of resistance.

T Ernst, S Aebi, A Zander, T Zander - BMJ Case Reports, 2022 - europepmc.org
Abstract BRAF V600E mutations are detected in 3%–10% of patients with multiple myeloma
(MM) and are associated with more aggressive disease, higher frequency of extramedullary …